학술논문
49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
Document Type
Abstract
Author
Source
In Journal of Thoracic Oncology April 2023 18(4) Supplement:S70-S71
Subject
Language
ISSN
1556-0864